The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy

AIDS

Volumn 17, Issue 7, 2003, Pages 963-969

  Smith, Colette J ^a   Sabin, Caroline A ^a   Lampe, Fiona C ^a   Kinloch De Loes, Sabine ^a   Gumley, Helen ^a   Carroll, Anne ^a   Prinz, Beth ^a   Youle, Mike ^a   Johnson, Margaret A ^a   Phillips, Andrew N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

CD4 cell count; Epidemiology; Highly active antiretrorival therapy; Immune reconstitution; Virological suppression

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; VIRAL LOAD; VIREMIA;

EID: 0037879430     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00004     Document Type: Article

References (31)

1. Phillips AN, Lee CA, Elford J, Janossy G, Kernoff PBA. The cumulative risk of AIDS as the CD4 lymphocyte count declines. J Acquir Immune Defic Syndr 1992; 5:148-152.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
3. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
4. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315:1194-1199.
5. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001; 42:134-139.
6. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, et al. Immunological responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70-79.
7. Wendland T, Furrer H, Vernazza PL, Frutig K, Christen A, Matter L, et al. HAART in HIV-infected patients: restoration of antigen-specific CD4 memory T-cell responses in vitro is correlated with CD4 memory T-cell reconstitutlon whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS 1999; 13:1857-1862.
8. Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, et al. Characterization of viral dynamics in human immunodeficiency virus type-1 infected patients treated with highly active antiretroviral therapy: relationships to host factors, cellular restoration, and virologic endpoints. J Infect Dis 1999; 179:799-807.
9. Pakker NG, Notermans DW, De Boer RJ, Roos MTL, de Wolf F, Hill A, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-214.
10. Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, et al. Immune reconstitutlon in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000; 181:358-363.
11. Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kaufmann RH, Meenhorst PL, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated immunodeficiency virus type 1-infected adults. J Infect Dis 1999; 180:1050-1056.
12. Kaufmann GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, Smith D, et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000; 14:2643-2651.
13. Bart PA, Rizzardi GP, Tambussi G, Chave JP, Chapuis AG, Graziosi C, et al. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. AIDS 2000; 14:1887-1897.
14. Staszewski S, Miller V, Sabin CA, Schlecht C, Gute P, Stamm S, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999; 13:951-956.
15. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14:959-969.
16. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA 1998; 280:35-40.
17. Kaufmann GR, Bloch M, Finlayson R, Zaunders JJ, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16:359-367.
18. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, et al. Increase and plateau of CD4 T-cell counts in the 31/2 years after initiation of potent antlretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:168-175.
19. Hejdeman B, Lenkel R, Leandersson AC, Hultstrom AL, Wahren B, Sandstrom E, et al. Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. AIDS Res Hum Retroviruses 2001; 17:277-286.
20. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-1686.
21. Havlir D, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, et al. Prevalence and predictive value of intermittent viraemia with combination HIV therapy. JAMA 2001; 286:171-179.
22. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Star Assoc 1979; 74:829-836.
23. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38:963-974.
24. Maini MK, Gilson RJC, Chavda N, Gill S, Fakoya A, Ross EJ, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med 1996; 72:27-31.
25. Bofill M, Janossy G, Lee CA, Macdonald-Burns D, Phillips AN, Sabin CA, et al. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol 1992; 88:243-252.
26. Phillips AN, Lee CA, Elford J, Janossy G, Bofill M, Timms A, et al. Prediction of progression to AIDS by analysis of CD4 lymphocyte counts in a haemophiliac cohort. AIDS 1989; 3:737-741.
27. 3 and viral loads below 50 copies/ml on antiretroviral therapy. AIDS 2002; 16:1-21.
28. Bisset LR, Cone RW, Fischer M, Battegay M, Vernazza PL, Dubs RW, et al. Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection. J Acquir Immune Defic Syndr 2001; 27:266-271.
29. Blankson JN, Gallant JE, Siliciano RF. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis 2001; 183:657-661.
30. Angel JB, Parato KG, Kumar A, Kravcik S, Badley AD, Fex C, et al. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. J Infect Dis 2001; 183:546-554.
31. Hunt P, Deeks S, Rodriguez B, Valdez H, Shade S, Abrams D, et al. Continued CD4+ T-cell count gains in patients with 4 years of suppressed viral load on HAART. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [Abstract 480-M].